| |
| | NEJM -- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin |
 | | Nicole Casadevall, M.D., Joelle Nataf, M.D., Béatrice Viron, M.D., Amir Kolta, M.D., Jean-Jacques Kiladjian, M.D., Philippe Martin-Dupont, M.D., Patrick Michaud, M.D., Thomas Papo, M.D., Valérie Ugo, M.D., Irène Teyssandier, B.S., Bruno Varet, M.D., and Patrick Mayeux, Ph.D. Full Text |
 | | Nicole Casadevall, M.D. Joelle Nataf, M.D. Béatrice Viron, M.D. Amir Kolta, M.D. Jean-Jacques Kiladjian, M.D. Philippe Martin-Dupont, M.D. Patrick Michaud, M.D. Thomas Papo, M.D. Valérie Ugo, M.D. Irène Teyssandier, B.S. Bruno Varet, M.D. and |
 | | Tangri, S., Mothe, B. R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., LiCalsi, C., Sette, A. Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity. |
| content.nejm.org /cgi/content/short/346/7/469 (1575 words) |
|